All filters
Slidesets
Real-life experiences - bottlenecks & hurdles- Nigeria, sub-Saharan Africa- Olufunmilayo Lesi, MD, MBA, FMCP, FWACP
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
Prevention transmission strategies prior to infection - People who inject drugs- Diana Sylvestre, MD
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
Prevention transmission strategies prior to infection - Incarceration- Lara Strick, MD, MS
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
Prevention transmission strategies through strengthening the health system- Maia Butshashvili, MD, MS, PhD
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
Micro-elimination as a strategy to reach global elimination- Jeffrey Lazarus, PhD, MIH, MA
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
Medicines Patent Pool’s approach to scale up access to HIV and HCV treatment- Esteban Burrone
Presented at:
International Viral Hepatitis Elimination Meeting (IVHEM) 2017
Slidesets
State of the ART: Integrase Inhibitors Resistance- Charles Boucher, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the virological support for reduced drug regimens?- Anne-Geneviève Marcelin, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
What is the clinical support for reduced drug regimens?- David Cooper, MD, DSc
Presented at:
European HIV Clinical Forum 2017
Slidesets
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy as a Switching Regimen in HIV-TR Cohort.- D. Yağcı-Çağlayık
Presented at:
European HIV Clinical Forum 2017
Slidesets
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.- D. Armenia
Presented at:
European HIV Clinical Forum 2017
Slidesets
French national survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 Virology Network).- A.G. Marcelin
Presented at:
European HIV Clinical Forum 2017
Slidesets
Clinical case presentation- Christina Mussini, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
In-vitro selection of resistance mutations to dolutegravir outside HIV-1 integrase.- Dr. Olivier Delelis
Presented at:
European HIV Clinical Forum 2017
Slidesets
Genetic variability of HIV-2 LTR regions impacts transcriptional activities.- Q. Le Hingrat
Presented at:
European HIV Clinical Forum 2017
Slidesets
Serum cystatine as a marker for estimated glomerular filtration rate (eGFR) assessment in HIV-1-infected patients with dolutegravir-based antiretroviral therapy (ART).- R. Palich
Presented at:
European HIV Clinical Forum 2017
Slidesets
Clinical case presentation- Miłosz Parczewski, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
Evolution of bone mineral density and MDRD in HIV-infected patients treated with dolutegravir based regimens: results at 48- weeks- A. D'Avino
Presented at:
European HIV Clinical Forum 2017
Slidesets
Prospects of immunotherapy for treatment- Michael Lederman, MD
Presented at:
European HIV Clinical Forum 2017
Slidesets
One pill a day?: Integration novel delivery systems into routine care- Giovanni Di Perri, MD, PhD
Presented at:
European HIV Clinical Forum 2017
Slidesets
TAF – The latest update, which questions remain to be answered?- Pietro Lampertico, MD, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Hepatitis B Cure: From Discovery to Regulatory Endpoints in HBV clinical research: A summary of the AASLD/EASL statement- Fabien Zoulim, MD, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
How does HBV interact with the immune system- Mala Maini, MD, PhD
Presented at:
International Workshop on HBV Cure 2017
Slidesets
Is immunomodulation really needed to cure HBV?- Harry Janssen, MD, PhD
Presented at:
International Workshop on HBV Cure 2017